Maximilian Diehn

Maximilian Diehn

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Maximilian Diehn

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ANAaron M. Newman
Aaron M. Newman
CSChloé B. Steen
Chloé B. Steen
CLChih Long Liu
Chih Long Liu
AGAndrew J. Gentles
Andrew J. Gentles
ACAadel A. Chaudhuri
Aadel A. Chaudhuri
AAAsh A Alizadeh
Ash A Alizadeh

20 July 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AGAndrew J Gentles
Andrew J Gentles
ANAaron M Newman
Aaron M Newman
CLChih Long Liu
Chih Long Liu
SBScott Bratman
Scott Bratman
WFWeiguo Feng
Weiguo Feng
AAAsh A Alizadeh
Ash A Alizadeh

9 April 2009 in Nature
Verified
Journal Article
Closed access
PDF file
MDMaximilian Diehn
Maximilian Diehn
RCRobert W. Cho
Robert W. Cho
NLNeethan A. Lobo
Neethan A. Lobo
TKTomer Kalisky
Tomer Kalisky
MDMary Jo Dorie
Mary Jo Dorie
MCMichael F. Clarke
Michael F. Clarke

6 April 2014 in Nature Medicine
Verified
Journal Article
Open access
PDF file
ANAaron M Newman
Aaron M Newman
SBScott Bratman
Scott Bratman
JTJacqueline To
Jacqueline To
JWJacob F Wynne
Jacob F Wynne
NENeville C W Eclov
Neville C W Eclov
MDMaximilian Diehn
Maximilian Diehn
Aaron Newman and his colleagues introduce a next-generation sequencing–based approach for the cost-effective detection and quantitation of tumor-derived circulating DNA in both early- and advanced-stage tumors and with high levels of sensitivity and specificity. CAPP-Seq (cancer personalized profiling by deep sequencing) can simultaneously detect multiple mutations and mutation types, including rearrangements. Here, utility is demonstrated for non–small-cell lung cancer. Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing ctDNA detection methods have insufficient sensitivity or patient coverage for broad clinical applicability. Here we introduce cancer personalized profiling by deep sequencing (CAPP-Seq), an economical and ultrasensitive method for quantifying ctDNA. We implemented CAPP-Seq for non–small-cell lung cancer (NSCLC) with a design covering multiple classes of somatic alterations that identified mutations in >95% of tumors. We detected ctDNA in 100% of patients with stage II–IV NSCLC and in 50% of patients with stage I, with 96% specificity for mutant allele fractions down to ∼0.02%. Levels of ctDNA were highly correlated with tumor volume and distinguished between residual disease and treatment-related imaging changes, and measurement of ctDNA levels allowed for earlier response assessment than radiographic approaches. Finally, we evaluated biopsy-free tumor screening and genotyping with CAPP-Seq. We envision that CAPP-Seq could be routinely applied clinically to detect and monitor diverse malignancies, thus facilitating personalized cancer therapy.

1 August 2009 in Cell
Verified
Journal Article
Closed access
YSYohei Shimono
Yohei Shimono
MZMaider Zabala
Maider Zabala
RCRobert W. Cho
Robert W. Cho
NLNeethan Lobo
Neethan Lobo
PDPiero Dalerba
Piero Dalerba
MCMichael F. Clarke
Michael F. Clarke

28 March 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
ANAaron M Newman
Aaron M Newman
ALAlexander F Lovejoy
Alexander F Lovejoy
DKDaniel M Klass
Daniel M Klass
DKDavid M Kurtz
David M Kurtz
JCJacob J Chabon
Jacob J Chabon
AAAsh A Alizadeh
Ash A Alizadeh
Circulating tumor DNA is detected with high sensitivity and specificity using molecular barcoding and in silico error correction. High-throughput sequencing of circulating tumor DNA (ctDNA) promises to facilitate personalized cancer therapy. However, low quantities of cell-free DNA (cfDNA) in the blood and sequencing artifacts currently limit analytical sensitivity. To overcome these limitations, we introduce an approach for integrated digital error suppression (iDES). Our method combines in silico elimination of highly stereotypical background artifacts with a molecular barcoding strategy for the efficient recovery of cfDNA molecules. Individually, these two methods each improve the sensitivity of cancer personalized profiling by deep sequencing (CAPP-Seq) by about threefold, and synergize when combined to yield ∼15-fold improvements. As a result, iDES-enhanced CAPP-Seq facilitates noninvasive variant detection across hundreds of kilobases. Applied to non-small cell lung cancer (NSCLC) patients, our method enabled biopsy-free profiling of EGFR kinase domain mutations with 92% sensitivity and >99.99% specificity at the variant level, and with 90% sensitivity and 96% specificity at the patient level. In addition, our approach allowed monitoring of NSCLC ctDNA down to 4 in 105 cfDNA molecules. We anticipate that iDES will aid the noninvasive genotyping and detection of ctDNA in research and clinical settings.